세계의 동물용 광견병 백신 시장 : 시장 규모, 점유율 및 동향 분석(용도별, 지역별), 부문별 예측(2025-2030년)

Rabies Veterinary Vaccines Market Growth & Trends:

The global rabies veterinary vaccines market size is expected to reach USD 1.10 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.9% from 2025 to 2030. The key factors driving the market include an increase in zoonotic disease awareness, boosting stray animal immunization coverage, and growing number of government initiatives with the motive of eradicating rabies by 2030. One of the main drivers propelling the market for animal rabies vaccinations is domestic animal vaccine awareness and education. There are numerous vaccines approved for use in domestic animal species, which include inactivated and modified-live virus vector products, products for IM and SC injection, products with immunization durations ranging from 1 to 3 years, and products with a range of minimum vaccination ages. Regular public education, responsible pet ownership, routine veterinary treatment and vaccinations, and continuous professional training are crucial elements of rabies prevention and control. By spreading knowledge about rabies transmission channels, the necessity of avoiding contact with wildlife and vaccinating wildlife with bait rabies vaccines are widely initiated, which greatly helps in reducing the spread of the disease from wildlife sources. Additionally, the vaccination improves domestic animals' general health and is linked to a decline in all-cause mortality rates.

Rabies is a deadly disease that attacks the central nervous system and has no effective treatment once clinical signs appear. It is estimated that 8.6 million dollars are spent globally on canine rabies, which is responsible for 98% of approximately 60,000 total rabies deaths that occur each year. The U.S. has made enormous efforts over the past 50 years to eradicate rabies in both animal and human populations. The number of animals infected with canine-mediated rabies has decreased from up to 10,000 cases per year because of the development of mass animal vaccination procedures and the enforcement of leash restrictions. Despite these developments, rabies continues to pose a major threat to public health and is still prevalent in raccoons, skunks, and foxes in wildlife reservoirs throughout the U.S.

All around the world, the COVID-19 pandemic has disrupted crucial health services. The United Against Rabies Forum, which advocates a 'One Health' strategy, was established in 2020 to hasten the achievement of this objective. The main components of the global rabies strategy include community involvement, better access to human rabies vaccines, and expanded mass dog vaccination. The advancement of rabies eradication strategies can be used as a marker for the equity of healthcare access in underserved populations and as an early indicator for the successful implementation of 'One Health'. The core element of the global rabies elimination strategy is mass dog vaccination, with a 70% coverage rate as the goal. The majority of endemic nations saw difficulties with distribution, volume reductions, and importation delays for dog vaccines. This was because dog vaccines initially did not fit within the category of necessary items. Budget restrictions prevented the production of dog vaccines even in countries such as Zambia where they are made locally.

Rabies is spread through saliva, which means the infection can be transmitted through infected animal bites. Rabies can be transmitted by monkeys, dogs, bats, or, in some cases, cats. 98% of rabies cases in Indonesia are caused by rabid dog bites. According to an article published in December 2021, by the National Library of Medicine over the past 10 years, there has been a slight increase in the number of animal rabies cases globally. In Thailand, a study was conducted between 2017 and 2018 to identify the characteristics of animal rabies, assess the relationship between monthly rabies incidence and understandable factors using generalized additive models, and estimate the geographical risk areas for rabies spread. According to the study, dogs are the most common species in Thailand that are infected by rabies. The majority of the infected dogs were owned, roaming freely, and were not vaccinated. The northeast region of the country has the highest concentrations of rabies cases, followed by the middle and southern regions. In the short term, the number of cases increased gradually after June and significantly from January in 2018. Such rabies-endemic countries are taking strong measures such as dog mass vaccination programs, wildlife bait rabies vaccination campaigns, and mandatory pet rabies vaccinations among others, which are anticipated to fuel the growth of the market.

Rabies Veterinary Vaccines Market Report Highlights:

• The companion animals segment held the largest revenue share in 2024 owing to the mandatory pet rabies vaccinations regulated in several countries, largely conducted mass dog vaccination programs, and significantly rising dog ownership rates
• The wildlife animals segment is anticipated to expand at the fastest CAGR of 4% over the forecast period owing to the rising wildlife rabies vaccination campaigns in developed regions
• North America is expected to maintain its lead over the forecast period. This is due to the region's high per capita animal healthcare spending and a large number of pet ownership rates. Almost every state in the U.S. mandates regular rabies vaccination for pets with the mission of eradicating rabies in the near future

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Vaccine Type
  • 1.2.3. Disease type
  • 1.2.4. Route of Administration
  • 1.2.5. Distribution Channel
  • 1.2.6. Regional Scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Rabies Veterinary VaccinesVariables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising animal rabies vaccination coverage in developing countries
    • 3.2.1.2. Increasing concerns over zoonotic diseases
    • 3.2.1.3. Implementation of mass dog vaccination campaigns in various countries
    • 3.2.1.4. Initiatives by market participants
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Limited access to veterinary services in under developed countries
• 3.3. Rabies Veterinary VaccinesAnalysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
    • 3.3.2.7. Estimated Animal Population by key Species, key Country, 2018-2024
• 3.4. Regulatory Framework
• 3.5. Pricing Analysis
• 3.6. COVID-19 impact Analysis

Chapter 4. Rabies Veterinary Vaccines market: Application Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Rabies Veterinary Vaccines market: Application Movement Analysis
• 4.3. Rabies Veterinary Vaccinesby Application Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Companion Animals
  • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.6. Livestock Animals
  • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 4.7. Wildlife Animals
  • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Rabies Veterinary Vaccines market: Distribution Channel Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Rabies Veterinary Vaccines market: Distribution Channel Movement Analysis
• 5.3. Rabies Veterinary Vaccinesby Distribution Channel Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Retail
  • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.6. E-Commerce
  • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• 5.7. Hospital/Clinic Pharmacies
  • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Rabies Veterinary Vaccines market: Regional Estimates & Trend Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. U.S. market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Canada market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Mexico market estimates and forecasts 2018 to 2030, (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. UK market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Germany market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. France market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Italy market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Spain market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.6. Sweden
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Sweden market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Denmark market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Norway market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.4.9. Rest of Europe
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Rest of Europe market estimates and forecasts 2018 to 2030, (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Japan market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. China market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. India market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Australia market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. South Korea market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Thailand market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.5.7. Rest of Asia-Pacific
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Rest of Asia-Pacific market estimates and forecasts 2018 to 2030, (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Brazil market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Argentina market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.6.3. Rest of LA
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Rest of LA market estimates and forecasts 2018 to 2030, (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. South Africa market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Saudi Arabia market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. UAE market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Kuwait market estimates and forecasts 2018 to 2030, (USD Million)
  • 6.7.5. Rest of MEA
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Rest of MEA market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Recent Developments & Impact Analysis by Key Market Participants
• 7.3. Company Market Share Analysis, 2024
• 7.4. Company overview
  • 7.4.1. Boehringer Ingelheim International GmbH
    • 7.4.1.1. Company Overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Zoetis Services LLC
    • 7.4.2.1. Company Overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Indian Immunologicals Ltd.
    • 7.4.3.1. Company Overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Merck & Co., Inc.
    • 7.4.4.1. Company Overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Virbac
    • 7.4.5.1. Company Overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. BiogenesisBago
    • 7.4.6.1. Company Overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Elanco
    • 7.4.7.1. Company Overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Ceva
    • 7.4.8.1. Company Overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. BroadChem Philippines Biopharma Corporation
    • 7.4.9.1. Company Overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
• 7.5. Strategy Mapping
  • 7.5.1. Mergers & Acquisitions
  • 7.5.2. Partnerships & Collaborations
  • 7.5.3. Expansions
  • 7.5.4. Others
• 7.6. List of Other Key Players